The Impact of Post-Mastectomy Radiation Therapy on Male Breast Cancer Patients-A Case Series

Journal Article · Wed Feb 01 04:00:00 EST 2012 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2011.01.010· OSTI ID:22056016

Yu, Edward ^[1]; Suzuki, Hiromichi ^[2]; Younus, Jawaid ^[3]; Elfiki, Tarek ^[4]; Stitt, Larry ^[5]; Yau, Gary; Vujovic, Olga; Perera, Francisco; Lock, Michael ^[1]; Tai, Patricia ^[6]

---

1. Department of Radiation Oncology, London Regional Cancer Program, London Health Science Centre, University of Western Ontario, Ontario (Canada)
2. Department of Internal Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka (Japan)
3. Department of Medical Oncology, London Regional Cancer Program, London Health Science Centre, University of Western Ontario, Ontario (Canada)
4. Department of Medical Oncology, Windsor Regional Cancer Centre, Windsor, Ontario (Canada)
5. Epidemiology Biostatistics, London Regional Cancer Program, London Health Science Centre, University of Western Ontario, Ontario (Canada)
6. Department of Radiation Oncology, Allan Blair Cancer Center, Regina, Saskatchewan (Canada)

Objective: To assess the impact of radiation management on male breast cancer (MBC) at London Regional Cancer Program (LRCP). Methods and Materials: Men with a diagnosis of breast cancer referred to LRCP were reviewed. The seventh American Joint Committee on Cancer staging system was used. Patients treated with and without post-mastectomy radiation therapy (PMRT) were analyzed. Disease-free survival (DFS) was defined as time duration from diagnosis to first recurrence. Overall survival (OS) was defined as time duration from pathologic diagnosis to death or last follow-up with any death defined as an event. Survival estimates were obtained using Kaplan-Meier methodology. Results: From January 1977 to December 2006, 81 men had invasive ductal carcinoma. The median age was 65 (range, 35-87 years). There were 15 Stage I, 40 Stage II, 20 Stage III, and 6 Stage IV patients. Median follow-up time was 46 months (range, 1-225 months). Of the 75 patients treated with curative intent, 29 did not receive PMRT and 46 completed PMRT. Patients who received PMRT demonstrated no benefit in overall survival (p = 0.872) but significantly better local recurrence free survival (p < 0.001) compared with those who did not receive RT. There was trend toward improving locoregional recurrence with PMRT in patients with high-risk features (node-positive, advanced stage, and {<=}2 mm or unknown surgical margin). The median, 5-year, and 10-year disease-free survival and overall survival for the 75 patients were 77.7 months, 66.3%, 32.7%, and 91.2 months, 73.9%, and 36.6%, respectively. Conclusion: The experience at LRCP suggests that high-risk MBC patients should consider PMRT to improve their chance of local recurrence-free survival.

• OSTI ID: 22056016
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 2 Vol. 82; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CARCINOMAS
DEATH
DIAGNOSIS
HAZARDS
MAMMARY GLANDS
MEN
PATIENTS
RADIOTHERAPY
SURGERY